KOMZIFTI (ziftomenib) Added to National Comprehensive Cancer Network (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated…
National Cancer Institute Broadens Partnership with Medidata to Bring Unmatched Continuity of Medical and Clinical Data for Lead Protocol Organizations
The Medidata Data Experience offering will enable the National Cancer Institute Lead…
Ride for a Cause, Rally for a Cure: Manipal Hospital Yeshwanthpur Leads the Charge Against Breast Cancer
BENGALURU, India, Nov. 4, 2025 /PRNewswire/ -- The streets of Bengaluru turned…
NCCN Celebrates Expanding Access to Cancer Treatment in Africa at 2025 AORTIC Meeting with New NCCN Adaptations for Sub-Saharan Africa
Updated cancer treatment guidelines reflect significant progress in cancer care delivery through…
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT…
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platforms Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers…
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase…
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of64Cu-PSMA-I&T for Prostate Cancer in Japan
PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Curium Group announced today that…
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET…
Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE)…
